BrightEdge is the innovation, impact investment and venture capital arm of the American Cancer Society. Today, our ACS Impact Venture Fund (AIVF) invests in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate ACS’s mission of ending cancer as we know it, for everyone.
